| Duration of treatment with albendazole for hepatic toxocariasis. | |
| | |
MedLine Citation:
|
PMID: 19259103 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
|
Authors:
|
Masahide Yoshikawa |
Publication Detail:
|
Type: Comment; Letter |
Journal Detail:
|
Title: Nature clinical practice. Gastroenterology & hepatology Volume: 6 ISSN: 1743-4386 ISO Abbreviation: - Publication Date: 2009 Mar |
Date Detail:
|
Created Date: 2009-03-04 Completed Date: 2009-06-17 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101226510 Medline TA: Nat Clin Pract Gastroenterol Hepatol Country: England |
Other Details:
|
Languages: eng Pagination: E1-2 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Albendazole / therapeutic use* Anthelmintics / therapeutic use* Humans Liver Diseases / parasitology* Toxocariasis / complications*, drug therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Anthelmintics; 54965-21-8/Albendazole |
| Comments/Corrections | |
Comment On:
|
Nat Clin Pract Gastroenterol Hepatol. 2008 Jun;5(6):344-8
[PMID:
18461059
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Plasma membrane expansion: a neuron's Herculean task.
Next Document: Proteomic and metabolic prediction of response to therapy in gastrointestinal cancers.